Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis

1 Apr 2006

Abstract excerpt

Major recent advances in the field of chromatin remodeling have dramatically changed our understanding of the ways in which genes are regulated. Epigenetic regulators such as histone deacetylases (HDACs) and histone acetyltransferases (HATs) are increasingly being implicated as direct or indirect components in the regulation of expression of neuronal, immune and other tissue specific genes. HDACs and HATs have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetics and Neurodevelopmental Disorders
Share to Neurogenetic and Muscular Disorders Research
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17998807
DOI: 10.4161/epi.1.2.2678

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple SclerosisPMID 17998807Read ↗

Efficacy of vafidemstat in experimental autoimmune encephalomyelitis highlights the KDM1A/RCOR1/HDAC epigenetic axis in multiple sclerosisSemantic proximity Read ↗

Putting the ‘HAT’ back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditionsSemantic proximity Read ↗

Loss of HDAC11 ameliorates clinical symptoms in a multiple sclerosis mouse modelSemantic proximity Read ↗

Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?Semantic proximity Read ↗

Histone deacetylases as targets for the treatment of human neurodegenerative diseasesSemantic proximity Read ↗

HDACs in the Brain: From Chromatin Remodeling to Neurodegenerative DiseaseSemantic proximity Read ↗

Multiple roles of HDAC inhibition in neurodegenerative conditionsSemantic proximity Read ↗

Epi-revolution in rheumatology: the potential of histone deacetylase inhibitors for targeted rheumatoid arthritis interventionSemantic proximity Read ↗

Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future PerspectiveSemantic proximity Read ↗

Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future PerspectivesSemantic proximity Read ↗

Histone deacetylase inhibitors: a patent review (2009 – 2011)Semantic proximity Read ↗

Epigenetic Modifications and Therapy in Multiple Sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.